8-KItem 5.02 · Officer/Director ChangeItem 9.01 · Financial Statements

IDEXX ($IDXX) and Nimrata Hunt, EVP Global Strategy & Commercial, agreed she’ll cease her role Apr 13,…

Filed with the SEC on · Summarized by InvestorsBot

IDEXX ($IDXX) and Nimrata Hunt, EVP Global Strategy & Commercial, agreed she’ll cease her role Apr 13, 2026 and serve as advisor through Jul 13, 2026. Separation announced Mar 24, 2026; role eliminated and treated as termination without cause. 🗓️🔁 #ExecMove #Governance

Under the separation agreement IDEXX will pay Dr. Hunt: $1.23M salary continuation (104 wks) + $984K target bonus (2 yrs), $50K COBRA lump sum, $10K transition, and tax prep up to $6K/yr (2025–26). Vested options exercisable; unvested awards forfeited. $IDXX 💵 #ExecComp #CorporateGovernance

Agreement includes a general release, non‑disparagement and cooperation covenants; Dr. Hunt remains bound by prior restrictive covenants (CIWP Agreement dated Jan 24, 2022). Advisory days after Apr 13 paid per‑diem based on base salary. 🔒 #Legal #Governance

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from IDEXX LABORATORIES INC /DE